The George Washington University School of Medicine, Washington, DC, USA.
Tourmaline Bio, Inc, New York, NY, USA.
Curr Atheroscler Rep. 2024 Nov 26;27(1):12. doi: 10.1007/s11883-024-01259-7.
The objective of this narrative review is to summarize data from recently published prospective observational studies that analyze the association between circulating interleukin-6 (IL-6) levels and cardiovascular clinical or imaging endpoints.
Higher levels of IL-6 are associated with a higher risk of cardiovascular death, major adverse cardiovascular events, myocardial infarction, stroke, peripheral artery disease, and heart failure. Imaging studies have also shown an association between IL-6 and carotid intima-media thickness progression, carotid plaque progression, severity, and vulnerability. These observations have been consistent across a wide range of study populations and after adjusting for traditional and emerging risk factors including high-sensitivity C-reactive protein. Robust epidemiologic evidence supports IL-6 as a central mediator of cardiovascular risk along with human genetic studies and mechanistic experiments. Ongoing clinical studies are testing the therapeutic hypothesis of IL-6 inhibition in patients with atherosclerotic cardiovascular disease or heart failure.
本文的目的是总结最近发表的前瞻性观察研究的数据，这些研究分析了循环白细胞介素 6（IL-6）水平与心血管临床或影像学终点之间的关系。
更高水平的 IL-6 与心血管死亡、主要不良心血管事件、心肌梗死、卒中等风险增加相关中、外周动脉疾病和心力衰竭。影像学研究还表明，IL-6 与颈动脉内膜中层厚度进展、颈动脉斑块进展、严重程度和易损性之间存在关联。这些观察结果在广泛的研究人群中以及在调整传统和新兴风险因素（包括高敏 C 反应蛋白）后是一致的。强有力的流行病学证据支持 IL-6 作为心血管风险的中心介质，以及人类遗传研究和机制实验。正在进行的临床研究正在测试在动脉粥样硬化性心血管疾病或心力衰竭患者中抑制 IL-6 的治疗假设。
